Après-demain has invested in Hoppen to accelerate its growth in the European digital healthcare market.

Target Information

Hoppen is a prominent French company specializing in digital transformation for healthcare facilities. Over the past four years, the company has experienced significant organic and external growth, establishing itself as a leader in providing phygital support to patients and healthcare establishments. This development has reduced the burden on healthcare professionals, enabling them to focus more on patient care.

Recently recognized as a winner of the French Tech 2030 award, Hoppen is now taking a significant step forward with the entry of Swiss firm Après-demain into its capital structure. Après-demain is the parent company of Debiopharm™, which operates in the life sciences sector. This investment is intended to accelerate Hoppen’s growth plans in Europe and solidify its leadership in digital solutions for patients before, during, and after hospitalization.

Industry Overview

The healthcare industry in France, much like in many parts of Europe, is undergoing a profound transformation driven by technological advancements and a growing demand for improved patient exper